VERTEX PHARMACEUTICALS INC / MA
Vertex Pharmaceuticals develops, manufactures and commercializes medicines for people with serious diseases, with a focus on specialty markets. Its approved medicines treat cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Its cystic fibrosis products include ALYFTREK, TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO; CASGEVY is a gene-editing therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, and JOURNAVX treats moderate-to-severe acute pain in adults. Vertex also develops clinical-stage programs for kidney diseases, neuropathic pain, type 1 diabetes, myotonic dystrophy type 1 and other serious conditions. Vertex sells medicines mainly to specialty pharmacies and distributors worldwide and to major wholesalers in the U.S. It promotes approved medicines to healthcare professionals and, in the U.S., directly to consumers. Vertex is headquartered in Boston, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $VRTX in the last 30 days.
See all $VRTX insider activity →Healthcare stocks rose on Monday, with the sector ETF up 0.88%. CMS projected lower Medicare Advantage premiums for 2027. JNJ, VRTX, HUM, EW, and MCK reported earnings or regulatory news, with some raising guidance. JNJ's cancer therapy received FDA approval, VRTX reported 12% revenue growth, and HUM raised EPS guidance. EW and MCK also raised their outlooks.
Nuvera, an Inizio Engage brand, announced winners of its 2026 Best-in-Class Patient Support Program Awards, with AbbVie, Sanofi/Regeneron, Pfizer, and Genentech among the top large pharma companies across various therapeutic areas. Rankings are based on feedback from over 2,300 physicians and healthcare staff. Winners will be recognized at the Informa Patient Pathways Congress in November. Nuvera also noted the increasing role of AI in patient support programs.
Needham kept its Buy rating on Vertex and increased its price target to $30 from $20, suggesting an 88.4% upside from the Nov 4 close of $15.92, according to the firm.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning VRTX (VERTEX PHARMACEUTICALS INC / MA). Coverage has skewed bullish: 6 bullish, 1 neutral, and 0 bearish.
Recent VRTX coverage spans financial news and earnings.
Guidance lift signals stronger demand for CF therapies and diversification, supporting a bullish outlook.
Recognition without material financial effect.
Analyst upgrade and higher target suggest upside potential.
Analyst upgrade may drive buying pressure.
Revenue beat and higher guidance.
AlphAI scores every news story that mentions VRTX with an AI model for sentiment and relevance, and aggregates insider trades from VERTEX PHARMACEUTICALS INC / MA's SEC EDGAR Form 4 filings. Figures refresh continuously.
Healthcare stocks rose on Monday, with the sector ETF up 0.88%. CMS projected lower Medicare Advantage premiums for 2027. JNJ, VRTX, HUM, EW, and MCK reported earnings or regulatory news, with some raising guidance. JNJ's cancer therapy received FDA approval, VRTX reported 12% revenue growth, and HUM raised EPS guidance. EW and MCK also raised their outlooks.
Nuvera, an Inizio Engage brand, announced winners of its 2026 Best-in-Class Patient Support Program Awards, with AbbVie, Sanofi/Regeneron, Pfizer, and Genentech among the top large pharma companies across various therapeutic areas. Rankings are based on feedback from over 2,300 physicians and healthcare staff. Winners will be recognized at the Informa Patient Pathways Congress in November. Nuvera also noted the increasing role of AI in patient support programs.
Needham kept its Buy rating on Vertex and increased its price target to $30 from $20, suggesting an 88.4% upside from the Nov 4 close of $15.92, according to the firm.
Piper Sandler kept its Neutral rating on Vertex but raised its price target to $20 from $16, a 25% increase. This implies a 25.6% upside from the Nov 4 close of $15.92.
Major U.S. indexes rallied on Wednesday, with the Dow up 3.0%, S&P 500 up 1.8%, and Nasdaq up 1.8%. Biotech stocks also rose, with the Nasdaq Biotechnology Index up 2.1%. Amgen reported $10.4B in Q3 revenue, Gilead raised full-year guidance, Vertex saw 12% revenue growth, Incyte increased sales guidance, and Merck narrowed its sales range. Shares of these companies rose between 2.6% and 4.4%.
Barclays kept its Overweight rating on Vertex Pharmaceuticals and increased its price target to $626 from $617, suggesting a 17.9% upside from the Nov 3 close of $530.76. Recent analyst price targets for the company range from $570 to $725.
JP Morgan reiterated its Overweight rating for Vertex Pharmaceuticals and increased its price target to $570 from $560, suggesting a 3% upside from the stock's recent close. Other analysts' recent price targets for the company range from $575 to $725.
Goldman Sachs kept its Buy rating on Vertex Pharmaceuticals (VRTX) and raised its price target to $725 from $654, suggesting a 31.1% upside from the Nov 2 close. Recent analyst price targets for VRTX range from $575 to $660.
Morgan Stanley kept its Overweight rating on Vertex Pharmaceuticals but reduced its price target to $660 from $665. This implies a 19.3% upside from the Nov 2 close of $553.15. Recent analyst price targets for the company range from $575 to $660.
Scotiabank kept its Sector Outperform rating on Vertex Pharmaceuticals and increased its price target to $660 from $558, suggesting a 19.3% upside from the Nov 2 close of $553.15. Recent analyst price targets for the company range from $563 to $650.
